잠시만 기다려 주세요. 로딩중입니다.

Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience

Radiation Oncology Journal 2021년 39권 1호 p.33 ~ 40
Ugurluer Gamze, Mustafayev Teuta Zoto, Gungor Gorkem, Atalar Banu, Abacioglu Ufuk, Sengoz Meric, Agaoglu Fulya, Demir Gokhan, Ozyar Enis,
소속 상세정보
 ( Ugurluer Gamze ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Mustafayev Teuta Zoto ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Gungor Gorkem ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Atalar Banu ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Abacioglu Ufuk ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Sengoz Meric ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Agaoglu Fulya ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology
 ( Demir Gokhan ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Medical Oncology
 ( Ozyar Enis ) - Acibadem Mehmet Ali Aydinlar University School of Medicine Department of Radiation Oncology

Abstract


Purpose: We aimed to present our initial clinical experience on the implementation of a stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic disease.

Materials and Methods: Twenty-one patients (24 lesions) with liver metastasis treated with SMART were included in this retrospective study. Step-and-shoot intensity-modulated radiotherapy technique was used with daily plan adaptation. During delivery, real-time imaging was used by acquiring planar magnetic resonance images in sagittal plane for monitoring and gating. Acute and late toxicities were recorded both during treatment and follow-up visits.

Results: The median follow-up time was 11.6 months (range, 2.2 to 24.6 months). The median delivered total dose was 50 Gy (range, 40 to 60 Gy); with a median fraction number of 5 (range, 3 to 8 fractions) and the median fraction dose was 10 Gy (range, 7.5 to 18 Gy). Ninety-three fractions (83.7%) among 111 fractions were re-optimized. No patients were lost to follow-up and all patients were alive except one at the time of analysis. All of the patients had either complete (80.9%) or partial (19.1%) response at irradiated sites. Estimated 1-year overall survival was 93.3%. Intrahepatic and extrahepatic progression-free survival was 89.7% and 73.5% at 1 year, respectively. There was no grade 3 or higher acute or late toxicities experienced during the treatment and follow-up course.

Conclusion: SMART represents a new, noninvasive and effective alternative to current ablative radiotherapy methods for treatment of liver metastases in oligometastatic disease with the advantages of better visualization of soft tissue, real-time tumor tracking and potentially reduced toxicity to organs at risk.

키워드

Liver; Metastases; Oligometastatic disease; Stereotactic radiation therapy; MRI; Image guidance

원문 및 링크아웃 정보

등재저널 정보